Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole

Malesci, Alberto; Savarino, Vincenzo; Zentilin, Patrizia; Belicchi, Monica; Mela, Giuseppe Sandro; Lapertosa, G; Bocchia, Paolo; Ronchi, G.; Franceschi, M.

doi:10.1016/s0016-5107(96)70055-x

Cited by 132 publications

(77 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, evidence suggests that even high dose proton pump inhibitor therapy "normalizing" esophageal acid exposure will not usually result in reversal of Barrett's esophagus (63,69). Specific therapy for the truly asymptomatic patient with Barrett's is not warranted in the absence of data supporting the reversal of Barrett's with therapy or a reduction in the development of adenocarcinoma.…”

Section: The Goals Of Therapy Of Barrett's Esophagus Are the Same As mentioning

confidence: 99%

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

Sampliner

1998

The American Journal of Gastroenterology

105

110

View full text Add to dashboard Cite

Section: The Goals Of Therapy Of Barrett's Esophagus Are the Same As mentioning

confidence: 99%

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

Sampliner

1998

The American Journal of Gastroenterology

105

110

View full text Add to dashboard Cite

“…9 Recent studies suggested a small but measurable decrease in the length of BE in patients treated with high-dose proton-pump inhibitor therapy. [10][11][12][13] However, no study has examined the effect of antisecretory therapy prior to the diagnosis of BE on the length of Barrett's segments in gastro-oesophageal reflux disease (GERD) patients with newly diagnosed BE. At the Southern Arizona Department of the Veterans Affairs (VA) Healthcare System, a single experienced endoscopist has been responsible for performing endoscopy and collecting information on prior therapy on newly referred patients with diagnosed or suspected BE over the past 20 years.…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7][8][9][10][11][12][13][14][15][16]. Of all patients, 139 (41%) had prior use of histamine-2 receptor antagonists, or proton-pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus.…”

mentioning

confidence: 99%

The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy

El–Serag

Aguirre

Kuebeler

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background : The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro‐oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus. Methods : A retrospective analysis of a well‐characterized large cohort of patients with Barrett's oesophagus diagnosed between 1981 and 2000. Aim : To compare the length of Barrett's oesophagus between patients who received acid suppressive therapy prior to their diagnosis to those who did not receive such therapy. Pharmacy records were obtained from Department of the Veterans Affairs computerized records and prospectively collected research records. We further examined the association between prior use of acid suppressive therapy and the length of Barrett's oesophagus in correlation analyses, as well as multivariate linear regression analyses while adjusting for differences in year of diagnosis, age, gender, ethnicity, and the presence of intestinal metaplasia of the gastric cardia. Results : There were 340 patients with Barrett's oesophagus first diagnosed between 1981 and 2000. The average length of Barrett's oesophagus at the time of first diagnosis was 4.4 cm (range: 0.5–16). Of all patients, 139 (41%) had prior use of histamine‐2 receptor antagonists, or proton‐pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus. The mean length of Barrett's oesophagus was significantly shorter in patients with prior use of proton‐pump inhibitors (3.4 cm) or proton‐pump inhibitors and histamine‐2 receptor antagonists (3.1 cm) when compared to those with none of these medications (4.8 cm). In the multivariate linear regression model, the prior use of proton‐pump inhibitors or either proton‐pump inhibitors or histamine‐2 receptor antagonists was an independent predictor of shorter length of Barrett's oesophagus (P = 0.0396). Conclusions : The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro‐oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Initially some physicians advocated regular use of proton pump inhibitors (PPIs), whereas some surgeons advocated antireflux surgery [15][16][17][18]. However, whilst isolated case reports have suggested regression of Barrett's esophagus following antireflux surgery, the rates of regression have been disappointing following both medical and surgical treatment of reflux [15,16]. Indeed, there are multiple reports of esophageal adenocarcinoma developing after antireflux surgery [17,[19][20][21], and many patients presenting with advanced stage esophageal cancer report long periods of PPI use.…”

Section: Introductionmentioning

confidence: 99%

Molecular biomarkers and ablative therapies for Barrett’s esophagus

Chisholm

Mayne

Hussey

et al. 2012

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole

Cited by 132 publications

References 17 publications

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy

Molecular biomarkers and ablative therapies for Barrett’s esophagus

Contact Info

Product

Resources

About